160 related articles for article (PubMed ID: 20975358)
21. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
22. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
23. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
24. Complex decision-making for BRCA1/2 carriers.
Matloff ET
Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
[No Abstract] [Full Text] [Related]
25. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
26. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
27. Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction.
Paradiso A; Muggia F
Ann Oncol; 2011 Jan; 22 Suppl 1():i5-6. PubMed ID: 21285151
[No Abstract] [Full Text] [Related]
28. Hereditary breast and ovarian cancer: risks and challenges. Proceedings of a meeting. September 10-12, 2009. Bari, Italy.
Ann Oncol; 2011 Jan; 22 Suppl 1():i5-68. PubMed ID: 21438196
[No Abstract] [Full Text] [Related]
29. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
U.S. Preventive Services Task Force
Ann Intern Med; 2005 Sep; 143(5):355-61. PubMed ID: 16144894
[TBL] [Abstract][Full Text] [Related]
30. The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review.
Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S31-3. PubMed ID: 20975359
[TBL] [Abstract][Full Text] [Related]
31. Study clarifies risk of breast, ovarian cancer among mutation carriers.
Reynolds T
J Natl Cancer Inst; 2003 Dec; 95(24):1816-8. PubMed ID: 14679145
[No Abstract] [Full Text] [Related]
32. Lessons learned from genetic testing.
Esserman L; Kaklamani V
JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
[No Abstract] [Full Text] [Related]
33. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
34. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
35. [Inherited breast and ovarian cancers].
Gerdes AM; Ejlertsen B
Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
[TBL] [Abstract][Full Text] [Related]
36. Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress.
Landsbergen KM; Brunner HG; Manders P; Hoogerbrugge N; Prins JB
Genet Couns; 2010; 21(4):423-37. PubMed ID: 21290972
[TBL] [Abstract][Full Text] [Related]
37. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
38. Risk reduction works for BRCA mutation carriers--with heavy costs.
Vanchieri C
J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
[No Abstract] [Full Text] [Related]
39. [Prophylactic surgery of mammary and ovarian carcinoma].
Lux MP; Bani MR; Fasching PA; Beckmann MW
Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
